John Qpublic @Jamesbridgebuilder
13 November, 10:59
Small Pox has always been the next step.

FDA approved a pill for small pox in 2018.
Yes a pill for a disease that is eradicated in the U.S.
Their excuse is just in case of bio-terrorism.
A company called SIGA got the call and has a contract with BARDA (The Biomedical Advanced Research and Development Authority) to supply the drug.

Here is the catch though and it's freaking HUGE.
"The efficacy of TPOXX may be reduced in immunocompromised
patients." A.K.A. everyone with a covid vax.
It gets much worse.
A dedicated drug-drug interaction study determined that drug interactions exist for co-administration of repaglinide and midazolam.
Wouldn't you know that both of those drugs are used in a form of a Covid vaccine.

So not only will it not work well but you could have deaths from drug interactions out the wazzu.
BTW SIGA is Agis backward. Agis is a huge elder health network.

This is a set up, it always was. They are trying to sacrifice those you love.
BE VERY AFRAID.

Notice: Undefined index: tg1tga_access in /home/admin/www/anonup.com/themes/default/apps/timeline/post.phtml on line 396
Bergers Book Reviews donated @BergersBookRev
15 November, 12:54
In response John Qpublic to his Publication
Two news drugs for a disease that is considered to be eradicated. Very strange.

https://www.cdc.gov/smallp...

Notice: Undefined index: tg1tga_access in /home/admin/www/anonup.com/themes/default/apps/timeline/post.phtml on line 396
John Qpublic @Jamesbridgebuilder
Indeed. And what are the chances they counter act with covid vaxs naturally? I would say just about zero.
Even if you don't buy into any conspiracy common sense should be throwing flags everywhere.
This is science going against science. Almost like they knew it was going to happen...
07:07 AM - Nov 16, 2021
In response Bergers Book Reviews to her Publication
Only people mentioned by Jamesbridgebuilder in this post can reply

No replys yet!

It seems that this publication does not yet have any comments. In order to respond to this publication from John Qpublic, click on at the bottom under it